Discover Juvise Pharmaceuticals
Home | History |
From LynaPharm to Juvise Pharmaceuticals
From 2002 to 2008
LynaPharm: a pharmaceutical company specialized in psychiatric disorders
In 2002, Frederic MASCHA took the opportunity of a first acquisition, Lysanxia® (prazepam), a psychiatric drug from Pfizer, to found a pharmaceutical company called LynaPharm, through a joint venture with the Italian pharmaceutical group, Sigma-Tau.
Later on, LynaPharm acquired the rights of Anafranil® (clomipramine), an antidepressant drug from Novartis, and Synedil® (sulpiride), for psychotic disorders from Astellas.
Frederic MASCHA and his holding company, Juvise, sold their LynaPharm shares to the Sigma-Tau group in 2008 to create Juvise Pharmaceuticals.
Since 2008
Juvise Pharmaceuticals: a European specialty pharmaceutical company
Following the sale of LynaPharm laboratories in 2008, Frederic MASCHA created Juvise Pharmaceuticals.
Juvise Pharmaceuticals is a specialty pharmaceutical company manufacturing and marketizing its own branded pharmaceutical specialties – acquired from large pharmaceutical companies – in 75 countries in the world.
Juvise Pharmaceuticals currently markets 9 specialty pharmaceutical products, essential in the treatment of cancer, cardiovascular, neurologic-psychiatric and rheumatic disorders: Arimidex® (anastrozole), Casodex® (bicalutamide), Esidrex® (hydrochlorothiazide), Sintrom® (acenocoumarol), Digoxin-Juvise® (digoxin), Entumin® (clotiapine), Insidon® (opipramol), Extovyl® (betahistine mesilate) and Lumirelax® (methocarbamol).
Story
LynaPharm NeuroSciences
A pharmaceutical company specializing in neuropsychiatry, in association with the Italian pharmaceutical group Sigma-Tau.
LynaPharm's key achievements:
- Profits made from the first year
- Quadrupled sales from 2006 years and a total of 25 M€
- Treatments marketed in 22 countries
LynaPharm acquires
Lysanxia®
(Pfizer)
LynaPharm acquires
Anafranil®
(Novartis)
LynaPharm acquires
Synedil®
(Astellas)
Acquires 100% de LynaPharm
Juvisé Pharmaceuticals
A pharmaceutical company specializing in oncology, cardiology and neuropsychiatry.
Key achievements of Juvisé Pharmaceuticals:
- An established product portfolio
- Treatments marketed in 75 countries
- A strong network of partner factories
Juvisé Pharmaceuticals acquires
Lumirelax®
(Thera France)
Extovyl® (Thera France)
Extovyl® (Thera France)
Juvisé Pharmaceuticals acquires
Entumin®
(Novartis)
Insidon® (Thera France)
Calmixène® (Thera France)
Insidon® (Thera France)
Calmixène® (Thera France)
Juvisé Pharmaceuticals takes in license
Proxeed Plus®
(Sigma-Tau)
Ezerex® (Sigma-Tau)
Ezerex® (Sigma-Tau)
Juvisé Pharmaceuticals acquires
Esidrex®
(Novartis)
Sintrom® (Novartis)
Digoxine-Juvisé® (Novartis)
Sintrom® (Novartis)
Digoxine-Juvisé® (Novartis)
Juvisé Pharmaceuticals acquires
Arimidex®
(AstraZeneca)
Casodex® (AstraZeneca)
Casodex® (AstraZeneca)
Juvisé Pharmaceuticals acquires
Pylera®
(Abbvie)